Role of Ablative Radiotherapy in the Management of Metastatic Disease: A Patient Data Registry
Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age18+
SponsorDuke University
About this trial
The purpose of this study is to provide a registry of participants in order to assess the acute adverse event rates following ablative radiotherapy for metastatic disease.
Eligibility criteria
This trial does not accept healthy volunteersQualifiers
Age ≥ 18 years of age
Radiographic evidence of metastatic disease (may include oligoprogression, oligorecurrence or oligometastasis) at the time of study enrollment
Planned to receive, currently receiving, or have completed hypofractionated image guided radiotherapy (ablative radiotherapy) to an extracranial site(s)
Patient must sign study-specific informed consent
Disqualifiers
None
Trial population
Patients at Duke University Health System Radiation Oncology treatment facilities or Durham VA Medical Center
Trial design
Design model
Case-only
Time perspective
Prospective
Treatments tested in this trial
Not listed
Trial groups
No trial groups listed
Trial outcomes
Primary outcomes
1
Occurrence of acute adverse events following radiotherapy
Time frame
90 DaysSponsors and contacts
Click on the lead sponsor to view all of their trials.
Source ClinicalTrials.gov